Assessing the real-world safety of fenofibric acid for hyperlipidemia: results from WHO-VigiAccess and FAERS databases
BackgroundFenofibric acid is a small-molecule fibrate that functions as an agonist of peroxisome proliferator-activated receptor alpha (PPARα) and serves as an inhibitor of liver fatty acid-binding protein. It is primarily prescribed for the management of hyperlipidemia, including conditions such as...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Frontiers Media S.A.
2025-11-01
|
| Seri Bilgileri: | Frontiers in Medicine |
| Konular: | |
| Online Erişim: | https://www.frontiersin.org/articles/10.3389/fmed.2025.1702197/full |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|